Literature DB >> 22772146

Contrast enhancement kinetics of normal breast parenchyma in dynamic MR mammography: effects of menopausal status, oral contraceptives, and postmenopausal hormone therapy.

Katrin Hegenscheid1, Carsten O Schmidt, Rebecca Seipel, René Laqua, Ralf Ohlinger, Norbert Hosten, Ralf Puls.   

Abstract

OBJECTIVES: To investigate effects of menopausal status, oral contraceptives (OC), and postmenopausal hormone therapy (HT) on normal breast parenchymal contrast enhancement (CE) and non-mass-like enhancing areas in magnetic resonance mammography (MRM).
METHODS: A total of 459 female volunteers (mean age 49.1 ± 12.5 years) underwent T1-weighted 3D MRM 1-5 min after bolus injection of gadobutrol. Quantitative analysis was performed in normal breast parenchyma by manually tracing regions of interest and calculating percentage CE. Semiquantitative analysis was performed in non-mass-like enhancing areas, and signal intensity changes were characterised by five predefined kinetic curve types. The influence of OC (n = 69) and HT (n = 24) on CE was studied using random effects models.
RESULTS: Breast parenchymal enhancement was significantly higher in premenopausal than in postmenopausal women (P < 0.001). CE decreased significantly with the use of OC (P = 0.01), while HT had negligible effects (P = 0.52). Prevalence of kinetic curve types of non-mass-like enhancement differed strongly between pre- and postmenopausal women (P < 0.0001), but was similar in OC users and non-OC users (P = 0.61) as well as HT users and non-HT users (P = 0.77).
CONCLUSIONS: Normal breast parenchymal enhancement and non-mass-like enhancing areas were strongly affected by menopausal status, while they were not affected by HT use and only moderately by OC use. KEY POINTS: Breast parenchymal enhancement at MR mammography is stronger in premenopausal than postmenopausal women. The prevalence of strong enhancing non-mass-like areas is greater before menopause. Such enhancing non-mass-like areas may impair lesion detection in premenopausal women. Breast parenchymal enhancement is only marginally affected by hormone use. Discontinuation of hormone use before MR mammography may be unnecessary.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22772146     DOI: 10.1007/s00330-012-2544-9

Source DB:  PubMed          Journal:  Eur Radiol        ISSN: 0938-7994            Impact factor:   5.315


  34 in total

1.  Estimation of breast volume and its variation during the menstrual cycle using MRI and stereology.

Authors:  Z Hussain; N Roberts; G H Whitehouse; M García-Fiñana; D Percy
Journal:  Br J Radiol       Date:  1999-03       Impact factor: 3.039

2.  Cohort profile: the study of health in Pomerania.

Authors:  Henry Völzke; Dietrich Alte; Carsten Oliver Schmidt; Dörte Radke; Roberto Lorbeer; Nele Friedrich; Nicole Aumann; Katharina Lau; Michael Piontek; Gabriele Born; Christoph Havemann; Till Ittermann; Sabine Schipf; Robin Haring; Sebastian E Baumeister; Henri Wallaschofski; Matthias Nauck; Stephanie Frick; Andreas Arnold; Michael Jünger; Julia Mayerle; Matthias Kraft; Markus M Lerch; Marcus Dörr; Thorsten Reffelmann; Klaus Empen; Stephan B Felix; Anne Obst; Beate Koch; Sven Gläser; Ralf Ewert; Ingo Fietze; Thomas Penzel; Martina Dören; Wolfgang Rathmann; Johannes Haerting; Mario Hannemann; Jürgen Röpcke; Ulf Schminke; Clemens Jürgens; Frank Tost; Rainer Rettig; Jan A Kors; Saskia Ungerer; Katrin Hegenscheid; Jens-Peter Kühn; Julia Kühn; Norbert Hosten; Ralf Puls; Jörg Henke; Oliver Gloger; Alexander Teumer; Georg Homuth; Uwe Völker; Christian Schwahn; Birte Holtfreter; Ines Polzer; Thomas Kohlmann; Hans J Grabe; Dieter Rosskopf; Heyo K Kroemer; Thomas Kocher; Reiner Biffar; Ulrich John; Wolfgang Hoffmann
Journal:  Int J Epidemiol       Date:  2010-02-18       Impact factor: 7.196

3.  Normal parenchymal enhancement patterns in women undergoing MR screening of the breast.

Authors:  Sanaz A Jansen; Vicky C Lin; Maryellen L Giger; Hui Li; Gregory S Karczmar; Gillian M Newstead
Journal:  Eur Radiol       Date:  2011-02-17       Impact factor: 5.315

4.  Physiologic changes in breast magnetic resonance imaging during the menstrual cycle: perfusion imaging, signal enhancement, and influence of the T1 relaxation time of breast tissue.

Authors:  Jean-Paul Delille; Priscilla J Slanetz; Eren D Yeh; Daniel B Kopans; Leoncio Garrido
Journal:  Breast J       Date:  2005 Jul-Aug       Impact factor: 2.431

5.  High grade and non-high grade ductal carcinoma in situ on dynamic MR mammography: characteristic findings for signal increase and morphological pattern of enhancement.

Authors:  H Neubauer; Mengxia Li; R Kuehne-Heid; A Schneider; W A Kaiser
Journal:  Br J Radiol       Date:  2003-01       Impact factor: 3.039

6.  Undetected malignancies of the breast: dynamic contrast-enhanced MR imaging at 1.0 T.

Authors:  Andrea Teifke; Alexander Hlawatsch; Thomas Beier; Toni Werner Vomweg; Simin Schadmand; Markus Schmidt; Hans-Anton Lehr; Manfred Thelen
Journal:  Radiology       Date:  2002-09       Impact factor: 11.105

7.  Outcome analysis and rational management of enhancing lesions incidentally detected on contrast-enhanced MRI of the breast.

Authors:  Andrea Teifke; Hans Anton Lehr; Toni Werner Vomweg; Alexander Hlawatsch; Manfred Thelen
Journal:  AJR Am J Roentgenol       Date:  2003-09       Impact factor: 3.959

8.  The protective mechanism of progesterone on blood-brain barrier in cerebral ischemia in rats.

Authors:  Jianping Wang; Chao Jiang; Xin Li; Chunling Liu; Ningning Cheng; Yujin Hao
Journal:  Brain Res Bull       Date:  2009-05-27       Impact factor: 4.077

9.  Benign and malignant breast lesions: differentiation with echo-planar MR imaging.

Authors:  C A Hulka; B L Smith; D C Sgroi; L Tan; W B Edmister; J P Semple; T Campbell; D B Kopans; T J Brady; R M Weisskoff
Journal:  Radiology       Date:  1995-10       Impact factor: 11.105

10.  Changes in magnetic resonance mammography due to hormone replacement therapy.

Authors:  Stefan O R Pfleiderer; Steffen Sachse; Dieter Sauner; Christiane Marx; Ansgar Malich; Susanne Wurdinger; Werner A Kaiser
Journal:  Breast Cancer Res       Date:  2004-03-16       Impact factor: 6.466

View more
  10 in total

Review 1.  Evaluation of background parenchymal enhancement on breast MRI: a systematic review.

Authors:  Bianca Bignotti; Alessio Signori; Francesca Valdora; Federica Rossi; Massimo Calabrese; Manuela Durando; Giovanna Mariscotto; Alberto Tagliafico
Journal:  Br J Radiol       Date:  2016-12-07       Impact factor: 3.039

2.  The relationship of breast density in mammography and magnetic resonance imaging in high-risk women and women with breast cancer.

Authors:  Marissa Albert; Freya Schnabel; Jennifer Chun; Shira Schwartz; Jiyon Lee; Ana Paula Klautau Leite; Linda Moy
Journal:  Clin Imaging       Date:  2015-08-06       Impact factor: 1.605

3.  Background parenchymal uptake during molecular breast imaging and associated clinical factors.

Authors:  Carrie B Hruska; Deborah J Rhodes; Amy Lynn Conners; Katie N Jones; Rickey E Carter; Ravi K Lingineni; Celine M Vachon
Journal:  AJR Am J Roentgenol       Date:  2015-03       Impact factor: 3.959

4.  High-background parenchymal enhancement in the contralateral breast is an imaging biomarker for favorable prognosis in patients with triple-negative breast cancer treated with chemotherapy.

Authors:  Chuanhui Xu; Jinhui Yu; Feifei Wu; Xuemei Li; Dongmin Hu; Guiming Chen; Gang Wu
Journal:  Am J Transl Res       Date:  2021-05-15       Impact factor: 4.060

5.  Background 99mTc-methoxyisobutylisonitrile uptake of breast-specific gamma imaging in relation to background parenchymal enhancement in magnetic resonance imaging.

Authors:  Hai-Jeon Yoon; Yemi Kim; Jee Eun Lee; Bom Sahn Kim
Journal:  Eur Radiol       Date:  2014-09-13       Impact factor: 5.315

Review 6.  Breast MRI: EUSOBI recommendations for women's information.

Authors:  Ritse M Mann; Corinne Balleyguier; Pascal A Baltzer; Ulrich Bick; Catherine Colin; Eleanor Cornford; Andrew Evans; Eva Fallenberg; Gabor Forrai; Michael H Fuchsjäger; Fiona J Gilbert; Thomas H Helbich; Sylvia H Heywang-Köbrunner; Julia Camps-Herrero; Christiane K Kuhl; Laura Martincich; Federica Pediconi; Pietro Panizza; Luis J Pina; Ruud M Pijnappel; Katja Pinker-Domenig; Per Skaane; Francesco Sardanelli
Journal:  Eur Radiol       Date:  2015-05-23       Impact factor: 5.315

7.  Association between MRI background parenchymal enhancement and lymphovascular invasion and estrogen receptor status in invasive breast cancer.

Authors:  Jun Li; Yin Mo; Bo He; Qian Gao; Chunyan Luo; Chao Peng; Wei Zhao; Yun Ma; Ying Yang
Journal:  Br J Radiol       Date:  2019-08-09       Impact factor: 3.039

8.  Additive value of texture analysis based on breast MRI for distinguishing between benign and malignant non-mass enhancement in premenopausal women.

Authors:  Yu Tan; Hui Mai; Zhiqing Huang; Li Zhang; Chengwei Li; Songxin Wu; Huang Huang; Wen Tang; Yongxi Liu; Kuiming Jiang
Journal:  BMC Med Imaging       Date:  2021-03-12       Impact factor: 1.930

9.  Prediction of background parenchymal enhancement on breast MRI using mammography, ultrasonography, and diffusion-weighted imaging.

Authors:  Akiko Kawamura; Hiroko Satake; Satoko Ishigaki; Mitsuru Ikeda; Reiko Kimura; Kazuhiro Shimamoto; Shinji Naganawa
Journal:  Nagoya J Med Sci       Date:  2015-08       Impact factor: 1.131

Review 10.  SHIP-MR and Radiology: 12 Years of Whole-Body Magnetic Resonance Imaging in a Single Center.

Authors:  Norbert Hosten; Robin Bülow; Henry Völzke; Martin Domin; Carsten Oliver Schmidt; Alexander Teumer; Till Ittermann; Matthias Nauck; Stephan Felix; Marcus Dörr; Marcello Ricardo Paulista Markus; Uwe Völker; Amro Daboul; Christian Schwahn; Birte Holtfreter; Torsten Mundt; Karl-Friedrich Krey; Stefan Kindler; Maria Mksoud; Stefanie Samietz; Reiner Biffar; Wolfgang Hoffmann; Thomas Kocher; Jean-Francois Chenot; Andreas Stahl; Frank Tost; Nele Friedrich; Stephanie Zylla; Anke Hannemann; Martin Lotze; Jens-Peter Kühn; Katrin Hegenscheid; Christian Rosenberg; Georgi Wassilew; Stefan Frenzel; Katharina Wittfeld; Hans J Grabe; Marie-Luise Kromrey
Journal:  Healthcare (Basel)       Date:  2021-12-24
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.